Boron Containing Doai Patents (Class 514/64)
  • Patent number: 10690675
    Abstract: Compositions and methods for enriching glycocompounds are disclosed which can comprise a glycocompound bound to a boronic acid compound which can be conjugated to a dendrimer.
    Type: Grant
    Filed: April 13, 2018
    Date of Patent: June 23, 2020
    Assignee: Georgia Tech Research Corporation
    Inventors: Ronghu Wu, Weixuan Chen
  • Patent number: 10689403
    Abstract: The present invention relates to a method for preparing a four-coordinated organic boron compound, and more specifically, to a method for preparing various and widespread four-coordinated organic boron compounds by directly using an aryl, heteroaryl, or vinyl-functional boronic acid, boroxine, or borate compound as a starting material and adding the compound to any bidentate N,O-ligand, O,O-ligand, or N,N-ligand.
    Type: Grant
    Filed: March 10, 2016
    Date of Patent: June 23, 2020
    Assignee: Korea Research Institute of Chemical Technology
    Inventors: Kee In Lee, Venkata Subbaiah Sadu, In Taek Hwang
  • Patent number: 10669290
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: January 2, 2019
    Date of Patent: June 2, 2020
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
  • Patent number: 10669287
    Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to A? peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: June 2, 2020
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Motomu Kanai, Yohei Soma, Jizhi Ni, Atsuhiko Taniguchi
  • Patent number: 10660909
    Abstract: What is described is a method for treating cancer in a patient in need of such treatment through the use of an antagonist to CXCR1 and/or CXCR2 receptors by administering a therapeutically effective amount of an antagonist of CXCR1 and/or CXCR2, or pharmaceutical compositions thereof, either alone as monotherapy, or in combination with at least one other anticancer therapy.
    Type: Grant
    Filed: February 23, 2018
    Date of Patent: May 26, 2020
    Assignee: Syntrix Biosystems Inc.
    Inventors: John A. Zebala, Dean Y. Maeda, Aaron D. Schuler
  • Patent number: 10662140
    Abstract: The present invention relates to a method for skin-whitening using a composition containing resveratryl triglycolate as an active ingredient, and more specifically, relates to a composition for skin-whitening containing resveratryl triglycolate or a cosmetically or pharmaceutically acceptable salt thereof as an active ingredient, a method for skin-whitening including applying or administering a composition containing resveratryl triglycolate or an acceptable salt thereof as an active ingredient to a subject, and a resveratryl triglycolate compound which has a skin-whitening effect, since the resveratryl triglycolate can inhibit melanin synthesis and brighten skin tone.
    Type: Grant
    Filed: November 9, 2016
    Date of Patent: May 26, 2020
    Assignee: KYUNGPOOK NATIONAL UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
    Inventors: Yong Chool Boo, Won Choul Park
  • Patent number: 10640520
    Abstract: Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmune disorder or hematological malignancies.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: May 5, 2020
    Assignee: MERCK PATENT GMBH
    Inventors: Markus Klein, Oliver Schadt, Philipp Haselmayer, Michael Busch
  • Patent number: 10633399
    Abstract: Disclosed are functionalized aminobenzoboroxoles compounds, method for preparing these compounds, and methods for treating cancers.
    Type: Grant
    Filed: August 15, 2016
    Date of Patent: April 28, 2020
    Assignee: Channel Therapeutics, Inc.
    Inventors: Kandalam V. Ramanujachary, Subash C. Jonnalagadda
  • Patent number: 10626128
    Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to A? peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: April 21, 2020
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Motomu Kanai, Yohei Soma, Jizhi Ni, Atsuhiko Taniguchi
  • Patent number: 10618918
    Abstract: Disclosed herein are antimicrobial compounds having the structure of the formula III? pharmaceutical compositions, the use and preparation thereof. The compounds are of the class of boronic acid derivatives, useful for antimicrobial treatment.
    Type: Grant
    Filed: March 14, 2019
    Date of Patent: April 14, 2020
    Assignee: QPEX BIOPHARMA, INC.
    Inventors: Scott Hecker, Raja K. Reddy
  • Patent number: 10526348
    Abstract: Provided is a compound which is bioapplicable and amyloid-selective, and is useful as an amyloid oxygenation catalyst applicable not only to A? peptides but also to other amyloids, and a preventive/therapeutic drug for an amyloid-related disease using the same.
    Type: Grant
    Filed: March 21, 2017
    Date of Patent: January 7, 2020
    Assignee: JAPAN SCIENCE AND TECHNOLOGY AGENCY
    Inventors: Motomu Kanai, Yohei Soma, Jizhi Ni, Atsuhiko Taniguchi
  • Patent number: 10479805
    Abstract: A beta-lactamase inhibitor having a formula (I). Also provided is a method of using the beta-lactamase inhibitor for prevention or treatment of diseases.
    Type: Grant
    Filed: October 19, 2018
    Date of Patent: November 19, 2019
    Assignee: WUHAN VISION PHARMACEUTICAL TECHNOLOGY CO., LTD.
    Inventors: Shiping Wu, Hongyu Xu, Xiangdong Hu
  • Patent number: 10464952
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: June 7, 2018
    Date of Patent: November 5, 2019
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson, Jodie Hamrick, Allison L. Zulli, Eugen F. Mesaros, Steven A. Boyd
  • Patent number: 10449226
    Abstract: The present invention relates to a method of treating cancer in a human and to pharmaceutical combinations useful in such treatment. In particular, the method relates to a cancer treatment method that includes administering a proteasome inhibiting compound, and N-{(1S)-2-amino-1-[(3-fluorophenyl)methyl]ethyl}-5-chloro-4-(4-chloro-1-methyl-1H-pyrazol-5-yl)-2-thiophenecarboxamide, or a pharmaceutically acceptable salt thereof, and optional additional antineoplastic agents, to a human in need thereof.
    Type: Grant
    Filed: December 20, 2016
    Date of Patent: October 22, 2019
    Assignee: Novartis AG
    Inventor: Rakesh Kumar
  • Patent number: 10435418
    Abstract: A reaction method comprising combining a carbonyl-substituted arylboronic acid or ester and an ?-effect amine in aqueous solution at a temperature between about ?5 C to 55 C, and a pH between 2 and 8 to produce an adduct. A process is also provided comprising: contacting a boron compound having a boron atom bonded to a sp2 hybridized carbon conjugated with a cis-carbonyl, the boron having at least one labile substituent, with an ?-effect amine, in a solvent for a time sufficient to form an adduct, which may proceed to further products.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: October 8, 2019
    Assignee: The Research Foundation for the State University o
    Inventors: Susan Bane Tuttle, Ozlem Dilek, Kamalika Mukherjee
  • Patent number: 10421870
    Abstract: A method to prepare a self-decontaminating surface, where that method includes dissolving tartaric acid in water, adding titanium (IV) isopropoxide to the tartaric acid solution to form a coating composition in water, and casting that coating composition onto a surface to form a coating having anti-microbial function.
    Type: Grant
    Filed: December 8, 2016
    Date of Patent: September 24, 2019
    Assignee: ALLIED BIOSCIENCE, INC.
    Inventors: Craig Grossman, Mai Ngo, Ronald Wysocki
  • Patent number: 10413549
    Abstract: The present invention relates to a compositions for and methods for cancer treatment, for example, hematopoietic cancers (e.g. B-cell Lymphoma). In other aspects, the invention provides methods for treating particular types of hematopoietic cancers, such as B-cell lymphoma, using a combination of one or more of the disclosed compounds and, for example, 26S proteasome inhibitors, such as, for example, Bortezomib. In another aspect the present invention relates to autoimmune treatment with the disclosed compounds. In another aspect, this invention relates to methods for identifying compounds, for example, compounds of the BH3 mimic class, that have unique in vitro properties that predict in vivo efficacy against B-cell lymphoma tumors and other cancers as well as autoimmune disease.
    Type: Grant
    Filed: October 24, 2017
    Date of Patent: September 17, 2019
    Assignee: Eutropics Pharmaceuticals, Inc.
    Inventors: David Richard, Michael H. Cardone
  • Patent number: 10352931
    Abstract: The present invention provides a diagnostic device allowing highly specific and efficient in vivo and/or in vitro detection of a bio marker in a broad range of bodily fluids or tissues. The diagnostic device is composed of a binding agent that specifically binds a bio marker present in the bodily fluid linked by a linker compound or layer to the substrate, which includes a metallic, a semiconductor, or a polymeric carrier. The present invention further provides methods using said device for the detection of bio markers, as well as kits comprising said device and suitable ingredients for the detections of bio markers in a bodily fluid. Furthermore, the invention provides suitable in vivo and in vitro applications of said binding agent for the detection of specific disease-related target structures.
    Type: Grant
    Filed: August 27, 2014
    Date of Patent: July 16, 2019
    Assignee: GILUPI GMBH
    Inventor: Björn Nowack
  • Patent number: 10314308
    Abstract: Compounds of formula (I) are as defined in the claims, and their use in compositions and methods for the control and/or prevention of microbial infection, particularly fungal infection, in plants and to processes for the preparation of these compounds.
    Type: Grant
    Filed: January 13, 2016
    Date of Patent: June 11, 2019
    Assignee: SYNGENTA PARTICIPATIONS AG
    Inventors: Ramya Rajan, Daniel Stierli, Renaud Beaudegnies, Peter Renold
  • Patent number: 10314795
    Abstract: The present invention includes compounds useful in preventing, treating or ameliorating Sigma-related disorders or diseases. The compounds of the invention may modulate cellular protein homeostasis, which includes: translation initiation, folding, processing, transport, and degradation (including ubiquitin selective autophagy) of proteins. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound. The present invention also includes methods of preventing, treating or ameliorating a Sigma-related disorder or disease in a subject in need thereof, the method comprising administering to the subject an effective amount of a Sigma-modulating compound, further comprising administering an effective amount of a compound that inhibits the ubiquitin proteasome system (UPS) and/or autophagic survival pathways.
    Type: Grant
    Filed: September 22, 2017
    Date of Patent: June 11, 2019
    Assignee: Drexel University
    Inventors: Felix J. Kim, Joseph M. Salvino
  • Patent number: 10293048
    Abstract: A pharmaceutical composition and preparing processes thereof. The composition comprises bortezomib or pharmaceutically acceptable salt or solvate thereof, tromethamine and an organic carboxylic acid, and the pH of the composition is from about 3.0 to 6.0.
    Type: Grant
    Filed: March 1, 2013
    Date of Patent: May 21, 2019
    Assignee: DR. REDDY'S LABORATORIES LIMITED
    Inventors: Navin Vaya, Harshal Prabhakar Bhagwatwar, Rakeshwar Bandichhor, Nirmal Khati, Riyaz Ahmed Shaik, Rahul Bhise, Yakaswamy Asalla, Rajkumar Bhimrao Shinde
  • Patent number: 10294246
    Abstract: Compounds of formula (I) are inhibitors of LMP7 and can be employed, inter alia, for the treatment of an autoimmune disorder or hematological malignancies.
    Type: Grant
    Filed: October 1, 2015
    Date of Patent: May 21, 2019
    Assignee: MERCK PATENT GMBH
    Inventors: Markus Klein, Oliver Schadt, Philipp Haselmayer, Michael Busch
  • Patent number: 10292976
    Abstract: The present invention aims to prevent and/or treat malaria using an antimalarial drug comprising, as an active ingredient, a metal chelator represented by the following formula (I), (III), (IV), (V), (VI), or (VII), such as tris(2-pyridylmethyl)amine.
    Type: Grant
    Filed: October 23, 2018
    Date of Patent: May 21, 2019
    Assignee: RIKEN
    Inventors: Akira Wada, Hiroki Hayase, Nobumoto Watanabe, Hiroyuki Osada, Takeshi Shimizu, Konstanty Wierzba
  • Patent number: 10214547
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: October 18, 2017
    Date of Patent: February 26, 2019
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
  • Patent number: 10183908
    Abstract: The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of kidney and/or liver disease.
    Type: Grant
    Filed: March 18, 2016
    Date of Patent: January 22, 2019
    Assignee: VECTUS BIOSYSTEMS LIMITED
    Inventor: Karen Annette Duggan
  • Patent number: 10125152
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: November 13, 2018
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
  • Patent number: 10117944
    Abstract: The present invention provides pharmacological compounds including an effector moiety conjugated to a binding moiety that directs the effector moiety to a biological target of interest. Likewise, the present invention provides compositions, kits, and methods (e.g., therapeutic, diagnostic, and imaging) including the compounds. The compounds can be described as a protein interacting binding moiety-drug conjugate (SDC-TRAP) compounds, which include a protein interacting binding moiety and an effector moiety. For example, in certain embodiments directed to treating cancer, the SDC-TRAP can include an Hsp90 inhibitor conjugated to a cytotoxic agent as the effector moiety.
    Type: Grant
    Filed: July 28, 2016
    Date of Patent: November 6, 2018
    Assignee: MADRIGAL PHARMACEUTICALS, INC.
    Inventors: Dinesh U. Chimmanamada, Weiwen Ying
  • Patent number: 10118936
    Abstract: The present invention is directed to arginase inhibitor compounds of formula IA or formula IB: or a pharmaceutically acceptable salt thereof, compositions containing these compounds, and methods of their use for the treatment and diagnosis of conditions characterized by upregulation of arginase, abnormally high arginase activity, or by abnormally low nitric oxide synthase activity.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: November 6, 2018
    Assignees: The Trustees of the University of Pennsylvania, AstraZeneca AB
    Inventors: David W. Christianson, Bruce Edward Tomczuk, Richard Scott Pottorf, Andrew Vargha Colasanti, Gary Lee Olson
  • Patent number: 10093685
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: October 9, 2018
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
  • Patent number: 10085452
    Abstract: An anti-fungal composition for the control of one or more target fungi (or a similar heterotrophic, hyphae-producing organism) that infect plant materials and are(is) separately controllable by a benzoxaborole and an anti-fungal compound of a preselected FRAC Target Site Code is disclosed, as is a method of its use. A composition contains a diluent medium having dissolved or dispersed therein a synergistic effective amount of each of a first and a second anti-fungal compound. The first anti-fungal compound is a benzoxaborole of Formula I. The second anti-fungal compound is other than a benzoxaborole and is known to control said one or more target species of fungus when utilized as the sole anti-fungal compound at a concentration greater than the synergistic effective amount and has a preselected FRAC Target Site Code of B, C, D, E, G, H, or M.
    Type: Grant
    Filed: July 7, 2017
    Date of Patent: October 2, 2018
    Assignee: The Penn State Research Foundation
    Inventors: Stephen Benkovic, Chunyu Liu
  • Patent number: 10072029
    Abstract: The present disclosure relates to a novel crystalline form of a proteasome inhibitor, and to the processes for the preparation thereof. The novel crystalline form according to the disclosure may be used in the preparation of pharmaceutical compositions for the treatment of cancer.
    Type: Grant
    Filed: February 10, 2016
    Date of Patent: September 11, 2018
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Marianne Langston, Debra Mazaik, Eric Elliott, Anton Peterson, Patricia Andres, Jing Teng
  • Patent number: 10065974
    Abstract: The invention relates to a novel class of compounds that exhibit activity inhibitory activity toward arginase, and pharmaceutical compositions comprising the compounds of the invention. Also provided herein are methods of treating cancer with the arginase inhibitors of the invention.
    Type: Grant
    Filed: October 28, 2016
    Date of Patent: September 4, 2018
    Inventors: Eric B. Sjogren, Jim Li, Michael Van Zandt, Darren Whitehouse
  • Patent number: 10011616
    Abstract: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.
    Type: Grant
    Filed: April 8, 2016
    Date of Patent: July 3, 2018
    Assignee: MMV MEDICINES FOR MALARIA VENTURE
    Inventors: Yong-Kang Zhang, Jacob J. Plattner, Robert T. Jacobs
  • Patent number: 10004730
    Abstract: A method for treating prostate cancer in a subject, comprising administering a therapeutically effective amount of at least one agent to the subject, wherein the agent is selected from: (a) a phenyl-substituted imidazole, or a pharmaceutically acceptable salt or ester thereof; or (b) a compound, or a pharmaceutically acceptable salt or ester thereof, having a formula I of: ?wherein R20 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing group, a boryl-containing group, a phosphine-containing group, amino, a thio-containing group, a seleno-containing group, halide, or a nitro-containing group; R21 is an alkanediyl or a substituted alkanediyl; a is 0 or 1; c is 0 or 1; X is C or S; R22 is a moiety that includes at least one divalent amino radical; and R23 is an aryl, substituted aryl, heteroaryl, substituted heteroaryl, heterocycloalkyl, substituted heterocycloalkyl, alkoxy, aryloxy, a silyl-containing
    Type: Grant
    Filed: March 13, 2017
    Date of Patent: June 26, 2018
    Assignee: University of Pittsburgh—Of the Commonwealth System of Higher Education
    Inventors: Zhou Wang, Joel Byron Nelson, Minh Bao Nguyen, John S. Lazo, Paul A. Johnston, Peter Wipf
  • Patent number: 9949995
    Abstract: A method of treating a bacterial infection in a subject in need thereof includes administering to the subject therapeutically effective amounts of at least one ?-lactam antibiotic and at least one triazolylmethyl boronic acid.
    Type: Grant
    Filed: September 6, 2016
    Date of Patent: April 24, 2018
    Assignee: Case Western Reserve University
    Inventors: Robert Bonomo, Fabio Prati, Emilia Caselli, Chiara Romagnoli
  • Patent number: 9944658
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: March 13, 2014
    Date of Patent: April 17, 2018
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
  • Patent number: 9944660
    Abstract: The present invention provides a tricyclic compound represented by general formula (I), a pharmaceutical salt thereof, or a stereoisomer thereof exhibits excellent antibacterial activity against Gram-negative bacteria resistant bacteria thereof, and also being excellent in terms of safety. Furthermore, the present invention provides production processes, pharmaceutical compositions comprising a tricyclic compound, a pharmaceutically acceptable salt thereof, or a stereoisomer thereof as an active ingredient and use thereof as a pharmaceutical agent. The compounds of the present invention are useful for the treatment and/or prevention of disease such as complicated urinary tract infections (cUTIs), nosocomial pneumonia, intra-abdominal infections (IAIs) or bacteremia.
    Type: Grant
    Filed: December 29, 2016
    Date of Patent: April 17, 2018
    Assignee: Daiichi Sankyo Company, Limited
    Inventors: Ajay Soni, Aditi Agarwal, Sangram Shesharao Deshmukh, Kedar Padmakar Purnapatre, Shinji Marumoto
  • Patent number: 9937154
    Abstract: The described invention relates to methods for preventing or treating graft-versus-host disease while preserving a graft-versus-tumor effect, increasing survival of, preserving alloreactivity, or a combination thereof in a patient with a tumor receiving a transplant. The described methods comprise administering to the patient a therapeutic amount of a pharmaceutical composition comprising a Rho kinase inhibitor compound, e.g., telmisartan or related angiotensin receptor blockers, and a pharmaceutically acceptable excipient. The therapeutic amount may be effective to attenuate graft-versus-host disease and to preserve the graft-versus-tumor effect of the transplant.
    Type: Grant
    Filed: June 3, 2016
    Date of Patent: April 10, 2018
    Assignee: Hackensak University Medical Center
    Inventors: David Schwartz, Sujatha Iyengar
  • Patent number: 9889146
    Abstract: Norvaline and/or other amino acids that are capable of being acylated onto tRNALeu by LeuRS, in combination with substituted benzoxaboroles, such as a compound having a structure according to formula III: and methods for decreasing the frequency of resistance and/or reducing the rate of resistance and/or suppressing the emergence of resistance that develops in bacteria exposed to a substituted benzoxaborole or salt thereof by administering a combination of a substituted benzoxaborole such as a compound of formula III or salt thereof and an amino acid or a salt thereof.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: February 13, 2018
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Michael Richard Kevin Alley, Katherine Widdowson
  • Patent number: 9861626
    Abstract: The present invention aims to prevent and/or treat malaria using an antimalarial drug comprising, as an active ingredient, a metal chelator represented by the following formula (I), (III), (IV), (V), (VI), or (VII), such as tris(2-pyridylmethyl)amine.
    Type: Grant
    Filed: January 9, 2015
    Date of Patent: January 9, 2018
    Assignee: RIKEN
    Inventors: Akira Wada, Hiroki Hayase, Nobumoto Watanabe, Hiroyuki Osada, Takeshi Shimizu, Konstanty Wierzba
  • Patent number: 9828391
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: July 18, 2016
    Date of Patent: November 28, 2017
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
  • Patent number: 9771382
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: June 27, 2016
    Date of Patent: September 26, 2017
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout, Randy W. Jackson
  • Patent number: 9750758
    Abstract: The technology described herein relates to pinacolyl boronate substituted stilbenes for the treatment of cancers, e.g. cancers expressing abnormally high levels of SREBP1.
    Type: Grant
    Filed: June 10, 2013
    Date of Patent: September 5, 2017
    Assignee: Thomas Jefferson University
    Inventors: Chenguang Wang, Jie Zhou
  • Patent number: 9717732
    Abstract: The invention provides a composition which comprises (a) a PDE3/PDE4 inhibitor which is 9,10-Dimethoxy-2-(2,4,6-trimethylphenylimino)-3-(N-carbamoyl-2-aminoethyl)-3,4,6,7-tetrahydro-2H-pyrimido[6,1-a]isoquinolin-4-one or a pharmaceutically acceptable acid addition salt thereof and (b) a ?2-adrenergic receptor agonist.
    Type: Grant
    Filed: March 17, 2014
    Date of Patent: August 1, 2017
    Assignee: VERONA PHARMA PLC
    Inventors: Michael J. A. Walker, Mario Cazzola, Luigino Calzetta
  • Patent number: 9682092
    Abstract: Methods of treating anti-inflammatory conditions through the use of boron-containing small molecules are disclosed.
    Type: Grant
    Filed: April 16, 2015
    Date of Patent: June 20, 2017
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Stephen J. Baker, Virginia Sanders, Tsutomu Akama, Carolyn Bellinger-Kawahara, Yvonne Freund, Kirk R. Maples, Jacob J. Plattner, Yong-Kang Zhang, Huchen Zhou, Vincent S. Hernandez
  • Patent number: 9637504
    Abstract: Described herein are compounds and compositions that modulate the activity of beta-lactamases. In some embodiments, the compounds described herein inhibit beta-lactamase. In certain embodiments, the compounds described herein are useful in the treatment of bacterial infections.
    Type: Grant
    Filed: May 23, 2016
    Date of Patent: May 2, 2017
    Assignee: VENATORX PHARMACEUTICALS, INC.
    Inventors: Christopher J. Burns, Denis Daigle, Bin Liu, Randy W. Jackson, Jodie Hamrick, Daniel McGarry, Daniel C. Pevear, Robert E. Lee Trout
  • Patent number: 9630935
    Abstract: The present invention relates to novel compounds and their use in the prophylactic and/or therapeutic treatment of hypertension and/or fibrosis.
    Type: Grant
    Filed: September 17, 2014
    Date of Patent: April 25, 2017
    Assignee: VECTUS BIOSYSTEMS LIMITED
    Inventor: Karen Annette Duggan
  • Patent number: 9617225
    Abstract: Novel 4,6-disubstituted aminopyrimidine derivatives with the following structure (I) have anti-HIV activity.
    Type: Grant
    Filed: August 23, 2013
    Date of Patent: April 11, 2017
    Assignee: VIROSTATICS SRL
    Inventors: Franco Lori, James Chafouleas, Davide De Forni, Antonio Solinas, Zoltán Varga, Zoltán Greff, László Örfi, György Kéri
  • Patent number: 9603775
    Abstract: The present invention is based, at least in part, on the identification of a pharmaceutical container formed, at least in part, of a glass composition which exhibits a reduced propensity to delaminate, i.e., a reduced propensity to shed glass particulates. As a result, the presently claimed containers are particularly suited for storage of pharmaceutical compositions and, specifically, a pharmaceutical solution comprising a pharmaceutically active ingredient, for example, VELCADE (bortezomib), STELARA (Ustekinumab), SIMPONI (golimumab), siltuximab, and AMG 403 (fulranumab).
    Type: Grant
    Filed: April 23, 2014
    Date of Patent: March 28, 2017
    Assignee: Corning Incorporated
    Inventors: Wendell P. Weeks, Robert Anthony Schaut, Steven Edward DeMartino, John Stephen Peanasky
  • Patent number: 9598443
    Abstract: This invention provides, among other things, novel compounds useful for treating protozoal infections, pharmaceutical compositions containing such compounds, as well as combinations of these compounds with at least one additional therapeutically effective agent.
    Type: Grant
    Filed: January 31, 2014
    Date of Patent: March 21, 2017
    Assignee: Anacor Pharmaceuticals, Inc.
    Inventors: Tsutomu Akama, Eric Easom, Yvonne Freund, Jacob J. Plattner, Jessica Sligar, Daitao Chen, Jennifer Freeman, Joe Perales